Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)

C. Philip Steuber; Vita J. Land; Curt I. Civin; Abdel H. Ragab; Jeffrey Krischer; Teresa J. Vietti

doi:10.1007/BF00169979

Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)

C. Philip Steuber, Vita J. Land, Curt I. Civin, Abdel H. Ragab, Jeffrey Krischer, Teresa J. Vietti

School of Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m² in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m²/day when given in combination with Ara-C.

Original language	English (US)
Pages (from-to)	379-382
Number of pages	4
Journal	Investigational New Drugs
Volume	5
Issue number	4
DOIs	https://doi.org/10.1007/BF00169979
State	Published - Dec 1987

Keywords

DHAD/AraC combination

ASJC Scopus subject areas

Pharmacology
Molecular Medicine

Access to Document

10.1007/BF00169979

Cite this

@article{9b8d71b834824e3fa7a1e0a871c99b64,

title = "Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)",

abstract = "To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m2/day when given in combination with Ara-C.",

keywords = "DHAD/AraC combination",

author = "Steuber, {C. Philip} and Land, {Vita J.} and Civin, {Curt I.} and Ragab, {Abdel H.} and Jeffrey Krischer and Vietti, {Teresa J.}",

year = "1987",

month = dec,

doi = "10.1007/BF00169979",

language = "English (US)",

volume = "5",

pages = "379--382",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Kluwer Academic Publishers",

number = "4",

}

TY - JOUR

T1 - Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)

AU - Steuber, C. Philip

AU - Land, Vita J.

AU - Civin, Curt I.

AU - Ragab, Abdel H.

AU - Krischer, Jeffrey

AU - Vietti, Teresa J.

PY - 1987/12

Y1 - 1987/12

N2 - To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m2/day when given in combination with Ara-C.

AB - To determine optimal dosage, Dihydroxyanthracenedione (DHAD) was given once daily for 3 days at dosage levels of 6, 7, 8, and 10 mg/m2 in combination with a 7-day continuous infusion of cytosine arabinoside (Ara-C). Nineteen of 20 children with leukemia who received these agents developed fever requiring hospitalization. There were 4 deaths 2 due to proven infection. One patient developed nonfatal cardiotoxicity. No other significant toxicity was noted. Responses were seen in 7 of 20 patients. The recommended DHAD dosage was 8 mg/m2/day when given in combination with Ara-C.

KW - DHAD/AraC combination

UR - http://www.scopus.com/inward/record.url?scp=0023629774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023629774&partnerID=8YFLogxK

U2 - 10.1007/BF00169979

DO - 10.1007/BF00169979

M3 - Article

C2 - 3481363

AN - SCOPUS:0023629774

SN - 0167-6997

VL - 5

SP - 379

EP - 382

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 4

ER -

Toxicity evaluation of dihydroxyanthracenedione (DHAD) in combination with cytosine arabinoside (Ara-C)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this